Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BioRestorative Therapies ( (BRTX) ) has issued an update.
On May 1, 2026, BioRestorative Therapies, Inc.’s compensation committee approved discretionary cash bonuses for its named executive officers for services rendered in 2025, reflecting increases over the prior year in both salary and equity-based awards. For 2025, Chief Executive Officer Lance Alstodt earned total compensation of about $2.41 million, VP of Research and Development Francisco Silva earned about $2.32 million, and Chief Financial Officer Robert Kristal earned about $0.80 million, signaling the board’s recognition of executive performance and ongoing investment in leadership.
The 2025 bonuses, to be paid in 2026, were granted on top of significant option awards valued under stock-based accounting rules, underscoring the company’s emphasis on equity incentives to align management with shareholder interests. Compared with 2024, the higher cash bonuses and option values for the top executives indicate a stronger compensation posture that may reflect the company’s assessment of progress in its operations and its desire to retain key talent in a competitive biotech market.
The most recent analyst rating on (BRTX) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on BioRestorative Therapies stock, see the BRTX Stock Forecast page.
Spark’s Take on BRTX Stock
According to Spark, TipRanks’ AI Analyst, BRTX is a Neutral.
The score is driven primarily by weak financial performance (large losses, significant cash burn, and a sharply reduced equity base) and bearish technicals (below key moving averages with negative MACD). Valuation provides only modest support because the negative P/E reflects ongoing unprofitability and no dividend data is available.
To see Spark’s full report on BRTX stock, click here.
More about BioRestorative Therapies
BioRestorative Therapies, Inc. is a biotechnology company focused on developing regenerative medicine and cell-based therapies. The company operates in the life sciences sector and relies on a leadership team that includes a chief executive officer, a vice president of research and development, and a chief financial officer to drive its research, development, and corporate strategy.
Average Trading Volume: 9,643,390
Technical Sentiment Signal: Sell
Current Market Cap: $5.74M
For detailed information about BRTX stock, go to TipRanks’ Stock Analysis page.